{"id":"intravitreal-injection-of-kh902","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL2108490","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"KH902 functions as a VEGF trap, binding and neutralizing VEGF-A and VEGF-B to prevent their interaction with VEGF receptors on endothelial cells. By blocking VEGF signaling, it reduces pathological neovascularization and vascular leakage associated with retinal diseases. The intravitreal injection route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.","oneSentence":"KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:55:43.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"}]},"trialDetails":[{"nctId":"NCT07144865","phase":"NA","title":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","status":"COMPLETED","sponsor":"Bojie Hu","startDate":"2024-12-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":8},{"nctId":"NCT06717412","phase":"NA","title":"Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy","status":"RECRUITING","sponsor":"Wang Yusheng","startDate":"2024-11-29","conditions":"Retinopathy of Prematurity (ROP)","enrollment":146},{"nctId":"NCT05728476","phase":"NA","title":"Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema","status":"RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2024-03-05","conditions":"Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept","enrollment":102},{"nctId":"NCT04782115","phase":"PHASE2","title":"Evaluation of RC28-E Injection in Diabetic Macular Edema","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-17","conditions":"Diabetic Macular Edema","enrollment":156},{"nctId":"NCT01436864","phase":"PHASE3","title":"A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2011-08","conditions":"Neovascular Age-related Macular Degeneration","enrollment":125},{"nctId":"NCT05642793","phase":"PHASE2","title":"Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-04-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":80},{"nctId":"NCT05414149","phase":"NA","title":"Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-09-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":80},{"nctId":"NCT05222633","phase":"","title":"Anti-VEGF in Real-world","status":"UNKNOWN","sponsor":"Wenbin Wei","startDate":"2022-01-01","conditions":"Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane","enrollment":1000},{"nctId":"NCT04990271","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2021-07-05","conditions":"Retinoblastoma","enrollment":92},{"nctId":"NCT03577899","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-09-25","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT03630952","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-12-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT02911311","phase":"NA","title":"Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-12","conditions":"Proliferative Diabetic Retinopathy","enrollment":226},{"nctId":"NCT04668703","phase":"NA","title":"Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-01-01","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic","enrollment":40},{"nctId":"NCT02802657","phase":"PHASE4","title":"Efficacy and Safety of \"Treat-and-Extend\" Regimen Versus \"Pro Re Nata\" of Conbercept in Age-related Macular Degeneration","status":"UNKNOWN","sponsor":"Xiaodong Sun","startDate":"2016-09","conditions":"Age-related Macular Degeneration","enrollment":141},{"nctId":"NCT02816710","phase":"PHASE4","title":"Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2016-07","conditions":"Proliferative Diabetic Retinopathy, Tractional Retinal Detachment","enrollment":112},{"nctId":"NCT03973125","phase":"EARLY_PHASE1","title":"Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-08-28","conditions":"Circumscribed Choroidal Haemangioma","enrollment":50},{"nctId":"NCT03426540","phase":"EARLY_PHASE1","title":"Intravitreal Conbercept After Vitrectomy","status":"COMPLETED","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2017-01-01","conditions":"Early Proliferative Diabetic Retinopathy","enrollment":50},{"nctId":"NCT03571282","phase":"EARLY_PHASE1","title":"Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-06","conditions":"Circumscribed Choroidal Haemangioma","enrollment":50},{"nctId":"NCT02577107","phase":"PHASE4","title":"Head to Head Study of Anti-VEGF Treatment.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-13","conditions":"Age-related Macular Degeneration","enrollment":12},{"nctId":"NCT03159884","phase":"PHASE4","title":"The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2015-10","conditions":"Polypoidal Choroidal Vasculopathy (PCV)","enrollment":300},{"nctId":"NCT02934841","phase":"PHASE2","title":"Conbercept in Choroidal Neovascularization Secondary to Uveitis","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2016-11","conditions":"Choroidal Neovascularization, Uveitis","enrollment":40},{"nctId":"NCT02194634","phase":"PHASE3","title":"Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2014-07","conditions":"Diabetic Macular Edema","enrollment":248},{"nctId":"NCT01157715","phase":"PHASE2","title":"A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2010-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":122},{"nctId":"NCT01809223","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-08","conditions":"Choroid Neovascularization Secondary to Degenerative Myopia","enrollment":176},{"nctId":"NCT01809236","phase":"PHASE2","title":"Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-05","conditions":"Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT01242254","phase":"PHASE1, PHASE2","title":"A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2009-08","conditions":"Neovascular Age-related Macular Degeneration","enrollment":36},{"nctId":"NCT01324869","phase":"PHASE1, PHASE2","title":"Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2010-04","conditions":"Diabetic Macular Edema","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Intravitreal injection of KH902","genericName":"Intravitreal injection of KH902","companyName":"Chengdu Kanghong Biotech Co., Ltd.","companyId":"chengdu-kanghong-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye. Used for Wet age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}